Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Indivior PLC

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Indivior (INDV – Research Report) and Certara (CERT ...

Analysts Offer Insights on Healthcare Companies: Indivior (INDV) and Certara (CERT)

Indivior plc (($INDV)) has held its Q3 earnings call. Read on for the main highlights of the call. Indivior PLC’s recent earnings call conveyed a g...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INDV	$32.75	+3.08%	2.23M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INDV	$32.75	+3.1%	2.23M
3
4
5
6

INDV

INDV

Get Indivior PLC Data in Excel

Get Indivior PLC Data in Excel